Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPADURVA: Durvalumab in Resectable Stage III NSCLC
NCT04202809Phase 2Unknown
- Sponsor
- Universitätsmedizin Essen
- Start
- Jan 2020
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Universitätsmedizin Essen. Status: unknown.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04202809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04202809.